KLF6 Antibody

1. blocking TGF-b signaling with the TGF-b receptor inhibitor SB431542 counteracted the effect of platelets on KLF6 expression and proliferation of HCC cells. Based on these findings, we conclude that platelet releasates, especially TGF-b, promote the proliferation of SMMC.7721 and HepG2 cells by decreasing expression of KLF6 PMID: 28638139
2. mitochondrial injury and apoptosis were significantly attenuated with overexpression of KLF6 in cultured human podocytes under hyperglycemic conditions. Finally, we observed a significant reduction in glomerular and podocyte-specific expression of KLF6 in human kidney biopsies with progression of diabetic kidney disease. PMID: 30115650
3. Decreased expression of KLF6-SV2 may be associated with the occurrence and development of colorectal cancer. KLF6-SV2 plays a role as tumor suppressor by efficiently blocking cell proliferation, arresting cell cycle and inducing apoptosis in colorectal cancer, which may be related to increased expression of p21 and Bax. PMID: 29084019
4. establish a novel molecular mechanism by which miR-148a-3p upregulates Tsp-4 expression in tenocytes to promote angiogenesis by targeting KLF6, which could be helpful for the treatment of tendinopathy in the future PMID: 29807011
5. KLF6 IVS 1-27 G > A may not be associated with cancer susceptibility, especially the susceptibility of unselected prostate cancer. PMID: 29970714
6. miR-181a is up-regulated in clear cell renal cell carcinoma and may act as a tumor promoting factor by targeting KLF6 expression. PMID: 29066014
7. Overexpression of KLF6-SV1 is associated with young patients, and loss of E-cadherin suggests that this variant correlated with the aggressiveness of nasopharyngeal carcinoma. PMID: 29854578
8. Overexpression of KLF6 markedly attenuated the oncogenic effect of miR-543 overexpression in clear cell renal cell carcinoma. PMID: 29101805
9. analyzed the expression of the wild type (WT) gene KLF6 and the oncogenic splice variant 1 (KLF6-SV1) at the mRNA level in subsets of T cells from CLL patients (n = 29), multiple myeloma patients (n = 6) and normal donors (n = 10) PMID: 29432497
10. Zymography assay demonstrated that KLF6 inhibited the activities of matrix metalloproteinase 9 (MMP-9) and weakened the expression of mesenchymal markers, such as snail, slug, and vimentin. Our study is the first to provide demonstrate that KLF6 functions as a tumor suppressor gene and prevents the metastasis of oral cancer cells. PMID: 28638268
11. DJ-1 knockdown increased KLF6 expression in bortezomib-resistant myeloma cells, and subsequent siRNA-mediated KLF6 knockdown rescued bortezomib-resistant myeloma cells from undergoing cell death. PMID: 27734217
12. Our study provides new evidence that interaction of KLF6 and Sp1 regulates basigin-2 expression in hepatocellular carcinoma PMID: 27057625
13. MIIP and PAK1 bind each other and a C-terminal polyproline domain of MIIP is required for PAK1 binding. Ectopically expressed MIIP consistently competed with Rac1-GTP for binding with the PAK1 p21-binding domain in endometrial cancer cells. PMID: 27760566
14. hypoxia induced an early and transient increase in KLF6 protein levels in HTR8/SVneo extravillous cytotrophoblast cells and in placental explants. Reoxygenation returned KLF6 protein to basal levels. Moreover, hypoxia-induced up-regulation of KLF6 expression was dependent on HIF-1alpha. These results indicate that KLF6 may mediate some of the effects of hypoxia in placental development. PMID: 27577710
15. The study highlights the central role of myeloid KLF6 in promoting intestinal inflammation. PMID: 26838049
16. study identifies a new mechanism by which KLF6 regulates NF-kappaB signaling, and how this mechanism is circumvented in glioblastoma through KLF6 loss. PMID: 28166199
17. our results established the significance of activating the KLF6-E2F1 axis in aggressive primary metastatic clear cell renal cell carcinoma PMID: 27780824
18. KLF6 overexpression suppressed the xenograft tumor growth. PMID: 27510817
19. KLF6 and KLF15 are targeted and suppressed in breast cancer cells by miR-4262. PMID: 27629257
20. KLF6 acts as a tumor suppressor in CMM cells and miR-4262 promotes the proliferation of CMM cells through KLF6-mediated EGFR inactivation and p21 upregulation. PMID: 27779691
21. These results suggest that KLF6 regulates MMP14 transcription and is a critical player of the gene expression network triggered during endothelial repair. PMID: 26850053
22. KLF6 is a novel regulator of human villous trophoblast fusion. PMID: 25537765
23. KLF6 overexpression partially phenocopied chaetocin treatment in DDLPS cells and induced phenotypic changes that were consistent with adipocytic differentiation, suggesting that the effects of increased H3K9me3 may be mediated through KLF6 PMID: 26193637
24. Study revealed that overexpression of miR-101 inhibited the proliferation, cell migration, invasion, and promoted apoptosis of glioblastoma stem cells by directly targeting KLF6 PMID: 25230316
25. Data show that MiR-1301 and miR-210 specifically target the tumor suppressive KLF6-FL isoform but not the oncogenic KLF6-SV1 isoform in hepatocellular carcinoma. PMID: 24921656
26. In this review, we focus on the functions, roles, and regulatory networks of these five KLFs in HCC, summarize key pathways, and propose areas for further investigation PMID: 25652467
27. Palmitic acid increases Ppargamma and Klf6 & Klf9 gene expression and promotes triglyceride accumulation in HepG2 cells. PMID: 25686501
28. report 2 unusual cytogenetic findings in a pediatric Ewing sarcoma, an insertion of the MIC2 gene encoding CD99 from Xp to 10p and a submicroscopic deletion of the well-known tumor supressor gene KLF6 PMID: 24322504
29. the possibility that overexpression of miR-181a contributes to the increased permeability of BTB by targeting KLF6, thereby revealing potential therapeutic targets for the treatment of brain gliomas. PMID: 25182666
30. Enhanced cell replication through increased KLF6 alternative splicing is a novel growth-promoting pathway of HGF that could contribute to the molecule's mitogenic activity in physiologic liver growth and hepatocellular carcinoma. PMID: 22859706
31. KLF6 protein is downregulated in human cutaneous malignant melanoma lesions compared with healthy skin tissue. KLF6 may be involved in tumour progression and may be a tumour suppressor and prognostic marker PMID: 24366496
32. Downregulation of KLF6 during the progression of breast cancer is independent of the mutations and occurs by a different mechanism. PMID: 24519062
33. Data indicate that upon IL-1beta stimulation, Kruppel-like factor 6 (KLF6) was recruited to promoters of a subset of NF-kappaB target genes in a p65-dependent manner, which was in turn required for the optimal binding of p65 to the target gene promoters. PMID: 24634218
34. KLF6 is required for optimal LPS-induced pro-inflammatory gene expression, acting cooperatively with NF-kappaB PMID: 24385430
35. KLF6 directly binds and represses PTTG1 expression during induction of myeloid differentiation. PMID: 23977008
36. This identifies KLF6 as a novel mediator of t(8;21) target gene regulation, providing a new mechanism for RUNX1-ETO transcriptional control. PMID: 24130502
37. KLF6 is a novel regulator of hepatic glucose and lipid metabolism in fatty liver. PMID: 23353867
38. GSK3beta phosphorylation of the KLF6 tumor suppressor promotes its transactivation of p21. PMID: 23085750
39. we have uncovered the mechanism of iNOS gene induction by identifying kruppel-like factor 6 (KLF6) as a critical transcription factor required for iNOS gene expression during Human respiratory syncytial virus infection PMID: 23831683
40. These findings implicate KLF6-SV1 as a key driver of breast cancer metastasis. PMID: 23345610
41. A novel effect of reactive oxygen species is determined by modulation of KLF6(Full) expression and its splice variants. PMID: 22486562
42. ah receptor and KLF6 proteins form an obligatory heterodimer necessary for nonconsensus XRE binding PMID: 23512538
43. Programmed cell death protein 4 (PDCD4) and Kruppel-like factor 6 (KLF6) were identified as critical regulators and surrogate markers of prostatic tissue architectures. PMID: 23219426
44. Low KLF6 expression is associated with osteosarcoma. PMID: 23322324
45. KLF6 is a putative tumor suppressor gene involved in osteosarcoma which can be used as a new therapeutic target and an important marker for early diagnosis and postoperative monitoring. PMID: 22855058
46. Wild-type KLF6 deletion and inactivation was involved in the growth, cell differentiation and other physiological processes of primary hepatocarcinoma. PMID: 21940380
47. ALK1 is upregulated in endothelial cells during vascular injury by a synergistic cooperative mechanism between KLF6 and specificity protein 1. PMID: 23048070
48. KLF6 expression is decreased in both clinical prostate cancer and a transgenic mouse model of prostate cancer with disease progression. PMID: 22782870
49. Deregulation of KLF6 may play a role in hepatocellular carcinoma pathogenesis. PMID: 20714872
50. An increased SV1/KLF6 ratio correlates with more aggressive Hepatocellular carcinoma. PMID: 22535637

Show More

Hide All

HGNC: 2235

OMIM: 176807

KEGG: hsa:1316

STRING: 9606.ENSP00000419923

UniGene: Hs.4055